Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Double Blind Placebo Controlled Study of RSLV-132 in Primary Sjogren's Syndrome
2016-001586-87Phase 2Completed
- Sponsor
- Resolve Therapeutics
- Start
- Jul 2016
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Sjögren's syndrome (SS) comparing RSLV-132 with Placebo (2 arms). Primary endpoint: Primary endpoint: Change in blood cell gene expression or serum protein levels indicative of reduced inflammation. Started Jul 2016; status: completed.
02
Drugs
RSLV-132
03
Conditions
Sjögren's syndrome (SS)
Beyond the preview
Go deeper on 2016-001586-87.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001586-87.